CLINICAL NEWS
Twice-daily dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim) was shown to be associated with lower rates of fatal and traumatic intracranial hemorrhage compared with warfarin, according to the results of a retrospective subanalysis published online, April 5, in Stroke, the Journal of the American Heart Association. » More |
|
Therapeutic oral anticoagulation with warfarin, without extra heparin, provides sufficient anticoagulation for patients on long-term warfarin who need primary percutaneous coronary intervention, according to a study published online, April 5, in the American Journal of Cardiology. » More |
|
As many as 80% of patients who are candidates for preventive treatments for migraine headaches could be helped by these treatments, the author of new guidelines issued by the American Academy of Neurology told Formulary. » More |
EDITOR’S PICK
Ivacaftor: A new emerging treatment option in the management of cystic fibrosis
Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, has been approved by FDA for patients aged 6 years and older who have the G551D mutation in the CFTR gene, offering a novel approach to the treatment of cystic fibrosis. » Click here. |
CONTINUING EDUCATION
E-prescribing, a paperless, real-time transmission of data, places pharmacists squarely within the healthcare technology team.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
FDA NEWS
FDA has issued a safety alert, warning patients, caregivers, and healthcare professionals about the dangers of accidental exposure to and improper storage and disposal of fentanyl patches.» More |
ASSOCIATION NEWS
The National Association of Boards of Pharmacy, the Accreditation Council for Pharmacy Education (ACPE), and ACPE providers have teamed up to create the CPE Monitor. This new system will allow for the electronic transmission of continuing pharmacy education data. » More |
Survey
a) Aging US population
b) Expanded coverage via HC reform
c) Price inflation by drug manufacturers
d) Growth in the specialty drug market
e) Increased incidence of key chronic diseases (eg, diabetes, CAD, asthma/COPD, etc.)
Click here and see what your colleagues think, too.
Want to see the results of our last survey regarding Medicare's coverage policy of immunosuppressive therapy following kidney transplantation? Click here. |
|
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
